Psychedelics Filament Health ships psilocybin drug to Australia, first country legally prescribing psychedelics The shipment was received by the medical cannabis company Little Green Pharma and its psychedelics subsidiary Rowan DunneJanuary 17, 2024
Psychedelics MAPS subsidiary raises over US$100M to support MDMA regulation The funding was led by the non-profit Helena, a diverse organization that aims to solve global problems Rowan DunneJanuary 5, 2024
Science and Research DEA sharply increases quantities of psychedelics, cannabinoids for 2024 research Substances being produced at a more rapid rate this year will include psilocybin, DMT and delta-9 THC Rowan DunneJanuary 4, 2024
Psychedelics Terran Biosciences obtains U.S. patent approval for catalogue of novel psychedelics They include two new forms of psilocybin, orally active DMT and 5-MeO-DMT, and an ibogaine derivative Rowan DunneDecember 11, 2023
News Psychedelic drug industry collaborations increased by 500% since 2019 United States had 63 partnerships followed by Canada with 29 and the United Kingdom with 15, according to the GlobalData firm Natalia Buendia CalvilloDecember 4, 2023
Psychedelics PharmAla Biotech ships first batch of MDMA and psilocybin to be used as medicines in Australia This is the first shipment that will be used specifically under the country's Authorized Prescriber Scheme enacted in July Rowan DunneNovember 7, 2023
Psychedelics Vancouver police raid Medicinal Mushroom Dispensary locations, owner arrested Dana Larsen owns three shops in Vancouver that openly sell psychedelics like psilocybin mushrooms, DMT and peyote Rowan DunneNovember 3, 2023
Psychedelics Māori group receives first psilocybin cultivation license in NZ to treat substance use disorders The license was granted to Rua Bioscience, a medical cannabis company based in Tairāwhiti Gisborne Rowan DunneOctober 30, 2023
Psychedelics Afghanistan Veteran gets Health Canada approval for psilocybin treatment from Apex Labs Kelsi Sheren said that other treatment methods for her PTSD and depression were ineffective Rowan DunneSeptember 28, 2023
Psychedelics Billionaire Steve Cohen’s Point 72 hedge fund takes 8.1% stake in Cybin It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety Rowan DunneSeptember 19, 2023